Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Clarithromycin · 4 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| Clarithromycin | EXPERIMENTAL | Clarithromycin is a lipophilic semi-synthetic macrolide antibiotic. The lipophilic nature of the drug allows it to easily penetrate into body fluids and tissues and accumulate intracellularly. Side effects are few, apart from trivial gastrointestinal complaints, and severe side effects are rarely observed during standard treatment. |
| Placebo | PLACEBO_COMPARATOR | Placebo comparator |
| A | ACTIVE_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| clarithromycin | DRUG | - |
| Amoxicillin | DRUG | Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID) |
| clarithromycin extended-release tablets | DRUG | 5-day course of clarithromycin extended-release tablets (2 x 500 mg QD) |
| clarithromycin immediate-release tablets | DRUG | 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID) |
| Zidovudine | DRUG | - |
| Didanosine | DRUG | - |
Inclusion Criteria: * patients aged 18 to 85 years and * previous acute myocardial infarction (AMI) or * previous or present angina pectoris and * signed informed concent Exclusion Criteria: * AMI or unstable angina pectoris within the last three months * revascularisation (PTCA or CABG) within t...
Clarithromycin is a small molecule antibiotic studied for Mycobacterium Avium-intracellulare Infection, Heart Disease, and Acute Bacterial Sinusitis (ABS). It is being developed by Abbott Laboratories (NYSE: ABT) and is currently in Phase 3 clinical trials for these indications.
Clarithromycin is a macrolide antibiotic that works by inhibiting bacterial protein synthesis. It binds to the 50S ribosomal subunit of susceptible bacteria, preventing the growth and replication of the microorganisms causing the infection.
Clarithromycin is being developed by Abbott Laboratories, a company publicly traded under the ticker symbol ABT on the New York Stock Exchange. Abbott is conducting clinical trials to evaluate the drug's safety and efficacy for multiple indications.
Clarithromycin is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trials are evaluating its use for Heart Disease and Acute Bacterial Sinusitis, while earlier phase trials have been completed.
Clarithromycin has been studied in several clinical trials. NCT00000971 evaluated its safety and effectiveness in children with Mycobacterium Avium Complex infections. NCT00121550, the CLARICOR trial, assessed its effect on mortality in patients with ischemic heart disease. NCT00644553 compared extended-release Clarithromycin to amoxicillin-clavulanate for acute bacterial sinusitis.
Clarithromycin is the generic name for the antibiotic also known as Biaxin. It is a macrolide antibiotic used to treat various bacterial infections, including those affecting the respiratory tract and skin. Abbott Laboratories markets the drug under the brand name Biaxin.